Functional improvement in coronary artery disease after 20 months of lipid-lowering therapy with policosanol

Advances in Therapy

Volumn 13, Issue 3, 1996, Pages 137-148

  Batista, Juan F ^a,b   Stüsser, Rodolfo J ^a   Padrón, René ^a   Sosa, Felix ^a   Pereztol, Osvaldo ^a   Pérez, Beatriz ^a  

^a UNIVERSITY OF HAVANA   (Cuba)

^b Centro de Investigaciones Clinicas   (Cuba)

Author keywords

201thallium labelled myocardial perfusion scintigraphy; coronary artery disease; ejection fraction; lipid lowering drug; maximum oxygen uptake; policosanol

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; PLACEBO; POLICOSANOL; THALLIUM;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; ORAL DRUG ADMINISTRATION; OXYGEN CONSUMPTION; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SCINTIGRAPHY;

EID: 0030002177     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Ornish D, Brown S, Scherwitz L, et al. Can lifestyle changes reverse coronary heart disease? Lancet. 1990;336:129-133.
2. Schuler G, Hambrecht R, Schierf G, et al. Regular exercise and low-fat diet. Effects on progression of coronary artery disease. Circulation. 1992;86:1-11.
3. Gould K. Reversal of coronary atherosclerosis. Clinical promise as the basis for noninvasive management of coronary artery disease. Circulation. 1994;90:1558-1571.
4. Gould K, Ornish D, Scherwitz L, et al. Changes in myocardial perfusion abnormalities by positron emission tomography after long-term, intense risk factor modification. JAMA. 1995;274:894-901.
5. Levine G, Keaney J, Vita J. Medical progress. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med. 1995;332:512-521.
6. Batista J, Stüsser R. Regresión de la aterosclerosis humana. Resultados de ensayos clínicos con el uso prolongado de hipolipemiantes. Rev Cub Med, in press.
7. Gould K, Martucci J, Goldberg D, et al. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium. Circulation. 1994;89:1530-1538.
8. Eichstadt H, Eskotter H, Hoffmann I, Amthaur H, Weidinger G. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease. Am J Cardiol. 1995;76:A122-A125.
9. Castaño G, Más R, Nodarse M, et al. One-year study of the efficacy and safety of policosanol (5 mg twice-daily) in the treatment of type II hypercholesterolemia. Curr Ther Res. 1995;56:296-303.
10. Arruzazabala M, Valdés S, Más R, Fernández I, Carbajal D. Effect of policosanol on platelet aggregation in healthy volunteers. Rev CENIC Cienc Biol. 1995;26:188. Abstract.
11. Noa M, Herrera M, Más R. Effect of ateromixol (policosanol) on endothelial injury in rats. Rev CENIC Cienc Biol. 1991;22:79-80.
12. Rodríguez-Echenique C, Mesa R, Más R, et al. Effects of policosanol chronically administered in male monkeys (macaca arctoides). Food Chem Toxicol. 1994;32:565-575.
13. Batista J, Stüsser R, Penichet M, Uguet E. Doppler-ultrasound pilot study of the effects of long-term policosanol therapy on carotid-vertebral atherosclerosis. Curr Ther Res. 1995;56:906-914.
14. Batista J, Stüsser R, Saéz F, Pérez B. Effect of policosanol on hyperlipidemia and coronary heart disease in middle-aged patients. A 14-month pilot study. Int J Pharmacol Ther. 1996;34:134-137.
15. Grundy S. National Cholesterol Education Program: second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Circulation. 1994;89:1329-1446.
16. Bruce R. Exercise testing of patients with coronary artery disease: principles and normal standards for evaluation. Ann Clin Res. 1971;3:323-332.
17. Multicenter Postinfarction Research Group. Risk stratification and survival after myocardial infarction. N Engl J Med. 1983;309:331-336.
18. Brown B, Stewart B, Zhao X, et al. What benefit can be derived from treating normocholesterolemic patients with coronary artery disease? Am J Cardiol. 1995;76(suppl):93C-97C.
19. Jukema J, Bruschke A, van Boven A, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The regression growth evaluation statin study (REGRESS). Circulation. 1995;91:2528-2540.
20. Benzuly K, Padgett R, Sanjay K, et al. Functional improvement precedes structural regression of atherosclerosis. Circulation. 1994;89:1810-1818.
21. Schmieder R, Schobel H. Is endothelial dysfunction reversible? Am J Cardiol. 1995;76(suppl):117A-121A.
22. White H, French J, Hamer A, et al. Frequent reocclusion of patient infarct-related arteries between 4 weeks and 1 year: effects of antiplatelet therapy. J Am Coll Cardiol. 1995;25:218-223.